Intellia Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-412.7M | $-519.0M | $-481.2M | $-474.2M | $-267.9M | $-134.2M | $-474.2M | $-85.3M |
| Depreciation & Amortization | $9.8M | $10.3M | $9.0M | $7.6M | $6.9M | $6.3M | $5.6M | $4.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $80.2M | $154.3M | $134.1M | $91.4M | $47.0M | $19.9M | $15.1M | $17.0M |
| Net Cash from Operating Activities | $-394.7M | $-348.9M | $-394.1M | $-333.3M | $-225.0M | $-49.9M | $-103.2M | $-61.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.1M | $5.8M | $14.0M | $13.6M | $12.8M | $3.6M | $6.8M | $6.4M |
| Business Acquisitions | — | $287.0K | $287.0K | $287.0K | — | — | — | — |
| Net Cash from Investing Activities | $228.0M | $125.6M | $-31.3M | $160.3M | $-550.8M | $-214.5M | $25.2M | $-260.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $131.5M | $185.7M | $130.3M | $583.0M | $736.7M | $371.8M | $76.4M | $40.2M |
| Net Change in Cash | $-35.2M | $-37.6M | $-295.1M | $410.0M | $-39.1M | $107.4M | $-1.6M | $-281.8M |
| Free Cash Flow | $-395.9M | $-354.7M | $-408.1M | $-346.8M | $-237.8M | $-53.5M | $-110.0M | $-67.6M |